Kissei's write-downs on a drug facing approval proceedings cut net profit despite operating recovery
Kissei's operating profit swung to ¥1.69bn from a ¥6.84bn loss in the half year, but impairment and inventory losses on assets tied to a drug facing approval proceedings cut net profit 33.3% and the full-year net profit guide to ¥10.0bn.